Quantum-Si Incorporated, The Protein Sequencing Company, announced the launch of new platform enhancements for Platinum, with the release of its new V2 Sequencing Kits. Combined with its first-to-market, next-generation protein sequencer™, these enhancements enable:
- Increased sequencing performance with assay improvements, including the addition of a new amino acid recognizer;
- Ability to identify unknown proteins with advanced analytical and inference tools;
- High reproducibility across runs; and
- Approximately a 3-fold reduction in cost per amino acid.
“Our newly introduced capabilities will provide researchers with additional insights into the proteome that have the potential to unlock scientific discovery only possible at the level of single amino acid recognition” said Jeff Hawkins, Chief Executive Officer of Quantum-Si. “With Platinum, we are striving to make protein sequencing accessible to every lab everywhere and now, with our V2 Sequencing Kits, more insights are possible with greater cost efficiency so that even more scientists can easily incorporate Platinum into their workflow.”
Quantum-Si is dedicated to meeting customer needs and enhancing their user experience. The recent launch marks an expansion of the Company’s current Platinum applications, now incorporating peptide barcodes and accommodating new sample types.
“These advancements not only ensure increased robustness and performance but also introduce novel protein inference analysis software, empowering customers to discover unknown proteins in their samples,” said Grace Johnston, Chief Commercial Officer of Quantum-Si. “With this launch, Quantum-Si is set to deliver unparalleled insights into protein characterization and function, catering to the evolving needs of our diverse customer base. Further, it reflects the value of next-generation protein sequencing as we expect that our platform will open new doors to unprecedented biologic insights and the molecules of life.”
Quantum-Si, The Protein Sequencing Company, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
SOURCE : BusinessWire